Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Three-year clinical outcome in all-comers with "silent" diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug-eluting stents: From the BIO-RESORT Silent Diabetes study.

Ploumen EH, Buiten RA, Kok MM, Doggen CJM, van Houwelingen KG, Stoel MG, de Man FHAF, Hartmann M, Zocca P, Linssen GCM, Doelman C, Kant GD, von Birgelen C.

Catheter Cardiovasc Interv. 2019 Oct 17. doi: 10.1002/ccd.28536. [Epub ahead of print]

PMID:
31625262
2.

Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.

Buiten RA, Ploumen EH, Zocca P, Doggen CJM, Danse PW, Schotborgh CE, Scholte M, van Houwelingen KG, Stoel MG, Hartmann M, Tjon Joe Gin RM, Somi S, Linssen GCM, Kok MM, von Birgelen C.

JACC Cardiovasc Interv. 2019 Sep 9;12(17):1650-1660. doi: 10.1016/j.jcin.2019.04.054. Epub 2019 Aug 14.

PMID:
31422087
3.

Quantitative EEG reactivity and machine learning for prognostication in hypoxic-ischemic brain injury.

Amorim E, van der Stoel M, Nagaraj SB, Ghassemi MM, Jing J, O'Reilly UM, Scirica BM, Lee JW, Cash SS, Westover MB.

Clin Neurophysiol. 2019 Oct;130(10):1908-1916. doi: 10.1016/j.clinph.2019.07.014. Epub 2019 Jul 25.

PMID:
31419742
4.

Coronary Angiography after Cardiac Arrest without ST-Segment Elevation.

Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, Rijpstra TA, Bosker HA, Blans MJ, Bleeker GB, Baak R, Vlachojannis GJ, Eikemans BJW, van der Harst P, van der Horst ICC, Voskuil M, van der Heijden JJ, Beishuizen A, Stoel M, Camaro C, van der Hoeven H, Henriques JP, Vlaar APJ, Vink MA, van den Bogaard B, Heestermans TACM, de Ruijter W, Delnoij TSR, Crijns HJGM, Jessurun GAJ, Oemrawsingh PV, Gosselink MTM, Plomp K, Magro M, Elbers PWG, van de Ven PM, Oudemans-van Straaten HM, van Royen N.

N Engl J Med. 2019 Apr 11;380(15):1397-1407. doi: 10.1056/NEJMoa1816897. Epub 2019 Mar 18.

PMID:
30883057
5.

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.

von Birgelen C, Zocca P, Buiten RA, Jessurun GAJ, Schotborgh CE, Roguin A, Danse PW, Benit E, Aminian A, van Houwelingen KG, Anthonio RL, Stoel MG, Somi S, Hartmann M, Linssen GCM, Doggen CJM, Kok MM.

Lancet. 2018 Oct 6;392(10154):1235-1245. doi: 10.1016/S0140-6736(18)32001-4. Epub 2018 Sep 22.

PMID:
30253879
6.

Stiffness-Induced Endothelial DLC-1 Expression Forces Leukocyte Spreading through Stabilization of the ICAM-1 Adhesome.

Schimmel L, van der Stoel M, Rianna C, van Stalborch AM, de Ligt A, Hoogenboezem M, Tol S, van Rijssel J, Szulcek R, Bogaard HJ, Hofmann P, Boon R, Radmacher M, de Waard V, Huveneers S, van Buul JD.

Cell Rep. 2018 Sep 18;24(12):3115-3124. doi: 10.1016/j.celrep.2018.08.045.

7.

Harvesting responses to single pulse electrical stimulation for presurgical evaluation in epilepsy.

Huiskamp G, van Blooijs D, van der Stoel M.

Clin Neurophysiol. 2018 Nov;129(11):2444-2445. doi: 10.1016/j.clinph.2018.08.011. Epub 2018 Aug 31. No abstract available.

PMID:
30193767
8.

Inferior acute myocardial infarction with anterior ST-segment elevations.

Bouhuijzen LJ, Stoel MG.

Neth Heart J. 2018 Oct;26(10):515-516. doi: 10.1007/s12471-018-1147-8. No abstract available.

9.

High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.

Zocca P, Kok MM, van der Heijden LC, van Houwelingen KG, Hartmann M, de Man FHAF, Stoel MG, Louwerenburg JHW, Knottnerus IL, Linssen GCM, Doggen CJM, von Birgelen C.

Int J Cardiol. 2018 Oct 1;268:11-17. doi: 10.1016/j.ijcard.2018.03.116. Epub 2018 May 23.

10.

Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial.

Kok MM, Zocca P, Buiten RA, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Stoel MG, van Houwelingen G, Linssen GCM, Doggen CJM, von Birgelen C.

EuroIntervention. 2018 Oct 20;14(8):915-923. doi: 10.4244/EIJ-D-18-00336.

11.

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.

Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C.

JACC Cardiovasc Interv. 2018 Mar 12;11(5):462-469. doi: 10.1016/j.jcin.2017.11.031.

12.

"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.

von Birgelen C, Kok MM, Sattar N, Zocca P, Doelman C, Kant GD, Löwik MM, van der Heijden LC, Sen H, van Houwelingen KG, Stoel MG, Louwerenburg JHW, Hartmann M, de Man FHAF, Linssen GCM, Doggen CJM, Tandjung K.

JACC Cardiovasc Interv. 2018 Mar 12;11(5):448-459. doi: 10.1016/j.jcin.2017.10.038. Epub 2018 Feb 14.

13.

Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents.

van der Heijden LC, Kok MM, Zocca P, Sen H, Löwik MM, Mariani S, de Man FHAF, Hartmann M, Stoel MG, van Houwelingen KG, Louwerenburg JHW, Linssen GCM, Doggen CJM, Grandjean JG, von Birgelen C.

J Am Heart Assoc. 2018 Jan 30;7(3). pii: e007212. doi: 10.1161/JAHA.117.007212.

14.

Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population.

Kok MM, von Birgelen C, Sattar N, Zocca P, Löwik MM, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Kant GD, Doelman C, Tjon Joe Gin M, Stoel MG, van Houwelingen G, Linssen GCM, IJzerman MJ, Doggen CJM, van der Heijden LC.

EuroIntervention. 2018 Oct 12;14(9):e1049-e1056. doi: 10.4244/EIJ-D-17-01067.

15.

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.

Zocca P, van der Heijden LC, Kok MM, Löwik MM, Hartmann M, Stoel MG, Louwerenburg JW, de Man FHAF, Linssen GCM, Knottnerus IL, Doggen CJM, van Houwelingen KG, von Birgelen C.

EuroIntervention. 2017 Nov 20;13(10):1168-1176. doi: 10.4244/EIJ-D-17-00634.

16.

Distinctive Responses in an In Vitro Human Dendritic Cell-Based System upon Stimulation with Different Influenza Vaccine Formulations.

Tapia-Calle G, Stoel M, de Vries-Idema J, Huckriede A.

Vaccines (Basel). 2017 Aug 9;5(3). pii: E21. doi: 10.3390/vaccines5030021.

17.

Three-Year Clinical Outcome of Patients with Coronary Disease and Increased Event Risk Treated with Newer-Generation Drug-Eluting Stents: From the Randomized DUTCH PEERS Trial.

van der Heijden LC, Kok MM, Löwik MM, Danse PW, Jessurun GAJ, Hartmann M, Stoel MG, van Houwelingen KG, Hautvast RWM, Linssen GC, Doggen CJM, von Birgelen C.

Cardiology. 2017;137(4):207-217. doi: 10.1159/000464320. Epub 2017 Apr 27.

PMID:
28445871
18.

Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial.

von Birgelen C, van der Heijden LC, Basalus MW, Kok MM, Sen H, Louwerenburg HW, van Houwelingen KG, Stoel MG, de Man FH, Linssen GC, Tandjung K, Doggen CJ, van der Palen J, Löwik MM.

JAMA Cardiol. 2017 Mar 1;2(3):268-276. doi: 10.1001/jamacardio.2016.5190.

PMID:
28114618
19.

Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial.

van der Heijden LC, Kok MM, Löwik MM, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Hartmann M, Linssen GC, Doggen CJM, von Birgelen C.

EuroIntervention. 2017 Apr 20;12(17):2128-2131. doi: 10.4244/EIJ-D-16-00571.

20.

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.

von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Gin RMTJ, Somi S, van Houwelingen KG, Stoel MG, de Man FHAF, Louwerenburg JHW, Hartmann M, Zocca P, Linssen GCM, van der Palen J, Doggen CJM, Löwik MM.

Lancet. 2016 Nov 26;388(10060):2607-2617. doi: 10.1016/S0140-6736(16)31920-1. Epub 2016 Oct 30.

PMID:
27806902
21.

Coronary angiography after cardiac arrest: Rationale and design of the COACT trial.

Lemkes JS, Janssens GN, Straaten HM, Elbers PW, van der Hoeven NW, Tijssen JG, Otterspoor LC, Voskuil M, van der Heijden JJ, Meuwissen M, Rijpstra TA, Vlachojannis GJ, van der Vleugel RM, Nieman K, Jewbali LS, Bleeker GB, Baak R, Beishuizen B, Stoel MG, van der Harst P, Camaro C, Henriques JP, Vink MA, Gosselink MT, Bosker HA, Crijns HJ, van Royen N; COACT investigators.

Am Heart J. 2016 Oct;180:39-45. doi: 10.1016/j.ahj.2016.06.025. Epub 2016 Jul 14.

PMID:
27659881
22.

Disentangling mechanisms involved in collagen pyridinoline cross-linking: The immunophilin FKBP65 is critical for dimerization of lysyl hydroxylase 2.

Gjaltema RA, van der Stoel MM, Boersema M, Bank RA.

Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7142-7. doi: 10.1073/pnas.1600074113. Epub 2016 Jun 13.

23.

Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.

van der Heijden LC, Kok MM, Danse PW, Schramm AR, Hartmann M, Löwik MM, Linssen GC, Stoel MG, Doggen CJ, von Birgelen C.

Am Heart J. 2016 Jun;176:28-35. doi: 10.1016/j.ahj.2016.02.020. Epub 2016 Mar 17.

PMID:
27264217
24.

Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).

Huisman J, van der Heijden LC, Kok MM, Danse PW, Jessurun GA, Stoel MG, van Houwelingen KG, Löwik MM, Hautvast RW, IJzerman MJ, Doggen CJ, von Birgelen C.

Am Heart J. 2016 May;175:121-9. doi: 10.1016/j.ahj.2016.02.012. Epub 2016 Feb 26.

25.

Safety and long-term effects of renal denervation: Rationale and design of the Dutch registry.

Sanders MF, Blankestijn PJ, Voskuil M, Spiering W, Vonken EJ, Rotmans JI, van der Hoeven BL, Daemen J, van den Meiracker AH, Kroon AA, de Haan MW, Das M, Bax M, van der Meer IM, van Overhagen H, van den Born BJ, van Brussel PM, van der Valk PH, Smak Gregoor PJ, Meuwissen M, Gomes ME, Oude Ophuis T, Troe E, Tonino WA, Konings CJ, de Vries PA, van Balen A, Heeg JE, Smit JJ, Elvan A, Steggerda R, Niamut SM, Peels JO, de Swart JB, Wardeh AJ, Groeneveld JH, van der Linden E, Hemmelder MH, Folkeringa R, Stoel MG, Kant GD, Herrman JP, van Wissen S, Deinum J, Westra SW, Aengevaeren WR, Parlevliet KJ, Schramm A, Jessurun GA, Rensing BJ, Winkens MH, Wierema TK, Santegoets E, Lipsic E, Houwerzijl E, Kater M, Allaart CP, Nap A, Bots ML.

Neth J Med. 2016 Jan;74(1):5-15.

26.

How should I treat multiple coronary aneurysms with severe stenoses?

Warisawa T, Naganuma T, Nakamura S, Hartmann M, Stoel MG, Louwerenburg JH, Basalus MW, von Birgelen C, Koo BK.

EuroIntervention. 2015 Nov;11(7):843-6. doi: 10.4244/EIJV11I7A171. No abstract available.

27.

Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study.

Kok MM, von Birgelen C, Lam MK, Löwik MM, van Houwelingen KG, Stoel MG, Louwerenburg JH, de Man FH, Hartmann M, Doggen CJ, van Til JA, IJzerman MJ.

EuroIntervention. 2016 Apr 20;11(13):1487-94. doi: 10.4244/EIJY15M10_06.

28.

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial.

Tandjung K, Lam MK, Sen H, de Man FH, Louwerenburg JH, Stoel MG, van Houwelingen KG, Linssen GC, van der Palen J, Doggen CJ, von Birgelen C.

EuroIntervention. 2016 Jul 20;12(4):431-40. doi: 10.4244/EIJY15M08_01.

29.

Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).

Sen H, Lam MK, Löwik MM, Danse PW, Jessurun GA, van Houwelingen KG, Anthonio RL, Tjon Joe Gin RM, Hautvast RW, Louwerenburg JH, de Man FH, Stoel MG, van der Heijden LC, Linssen GC, IJzerman MJ, Tandjung K, Doggen CJ, von Birgelen C.

JACC Cardiovasc Interv. 2015 Jun;8(7):889-99. doi: 10.1016/j.jcin.2015.01.033. Epub 2015 May 20.

30.

Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo.

Stoel M, Pool J, de Vries-Idema J, Zaaraoui-Boutahar F, Bijl M, Andeweg AC, Wilschut J, Huckriede A.

PLoS One. 2015 May 1;10(5):e0125228. doi: 10.1371/journal.pone.0125228. eCollection 2015.

31.

Assessment of the relation between initial culprit vessel patency in acute ST-elevation myocardial infarction and endothelial function.

Kandhai-Ragunath JJ, Jørstad HT, de Wagenaar B, de Man FH, Stoel MG, van Es J, Doelman CJ, Doggen CJ, Peters RJ, von Birgelen C.

EuroIntervention. 2014 Nov;10(7):784-91. doi: 10.4244/EIJV10I7A137.

32.

Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.

van Houwelingen KG, Sen H, Lam MK, Tandjung K, Löwik MM, de Man FH, Louwerenburg JH, Stoel MG, Hartmann M, Linssen GC, Doggen CJ, von Birgelen C.

Catheter Cardiovasc Interv. 2015 Feb 15;85(3):E76-82. doi: 10.1002/ccd.25713. Epub 2014 Nov 1.

PMID:
25339110
33.

Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial.

Sen H, Lam MK, Tandjung K, Basalus MW, de Man FH, Louwerenburg JH, Stoel MG, van Houwelingen GK, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, van der Palen J, von Birgelen C.

EuroIntervention. 2014 Oct;10(6):664-71. doi: 10.4244/EIJV10I6A117.

34.

Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry.

Sen H, Lam MK, Tandjung K, Löwik MM, van Houwelingen KG, Stoel MG, Louwerenburg HW, de Man FH, Linssen GC, Grandjean JG, Doggen CJ, von Birgelen C.

Int J Cardiol. 2014 Oct 20;176(3):885-90. doi: 10.1016/j.ijcard.2014.08.036. Epub 2014 Aug 13.

35.

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial.

Löwik MM, Lam MK, Sen H, Tandjung K, van Houwelingen KG, de Man FH, Stoel MG, Louwerenburg JH, Linssen GC, Doggen CJ, von Birgelen C.

EuroIntervention. 2015 Mar;10(11):1276-9. doi: 10.4244/EIJY14M08_11.

36.

Sialic acids sweeten a tumor's life.

Büll C, Stoel MA, den Brok MH, Adema GJ.

Cancer Res. 2014 Jun 15;74(12):3199-204. doi: 10.1158/0008-5472.CAN-14-0728. Epub 2014 May 15. Review.

37.

Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial.

Lam MK, Sen H, Tandjung K, Löwik MM, Basalus MW, Mewes JC, Stoel MG, van Houwelingen KG, Linssen GC, Ijzerman MJ, Doggen CJ, von Birgelen C.

Catheter Cardiovasc Interv. 2015 Mar;85(4):524-31. doi: 10.1002/ccd.25518. Epub 2014 May 8.

PMID:
24753036
38.

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial.

Lam MK, Tandjung K, Sen H, Basalus MW, van Houwelingen KG, Stoel MG, Louwerenburg JW, Linssen GC, Saïd SA, Nienhuis MB, de Man FH, van der Palen J, von Birgelen C.

EuroIntervention. 2015 Jun;11(2):180-7. doi: 10.4244/EIJV11I2A32.

39.

Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.

Sen H, Lam MK, Tandjung K, Löwik MM, Stoel MG, de Man FH, Louwerenburg JH, van Houwelingen GK, Linssen GC, Doggen CJ, Basalus MW, von Birgelen C.

Catheter Cardiovasc Interv. 2015 Jan 1;85(1):74-81. doi: 10.1002/ccd.25464. Epub 2014 Mar 14.

PMID:
24585502
40.

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.

von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.

Lancet. 2014 Feb 1;383(9915):413-23. doi: 10.1016/S0140-6736(13)62037-1. Epub 2013 Oct 31. Erratum in: Lancet. 2014 Feb 1;383(9915):412.

PMID:
24183564
41.

Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.

Tandjung K, Sen H, Lam MK, Basalus MWZ, Louwerenburg JHW, Stoel MG, van Houwelingen KG, de Man FHAF, Linssen GCM, Saïd SAM, Nienhuis MB, Löwik MM, Verhorst PMJ, van der Palen J, von Birgelen C.

J Am Coll Cardiol. 2013 Jun 18;61(24):2406-2416. doi: 10.1016/j.jacc.2013.04.005. Epub 2013 Apr 16.

42.

Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial.

Tandjung K, Basalus MW, Sen H, Stoel MG, van Houwelingen KG, Louwerenburg JH, de Man FH, Linssen GC, Saïd SA, Kleijne MA, van der Palen J, von Birgelen C.

Catheter Cardiovasc Interv. 2013 Sep 1;82(3):396-405. doi: 10.1002/ccd.24848. Epub 2013 Mar 8.

43.

Giant coronary aneurysm in Churg-Strauss syndrome.

Hartmann M, Wajon EM, van Houwelingen GK, Stoel MG, von Birgelen C.

EuroIntervention. 2012 Oct;8(6):760-1. doi: 10.4244/EIJV8I6A116. No abstract available.

44.

Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial).

Tandjung K, van Houwelingen KG, Jansen H, Basalus MW, Sen H, Löwik MM, Stoel MG, Louwerenburg JH, de Man FH, Linssen GC, Nijhuis R, Nienhuis MB, van der Palen J, Stolk RP, von Birgelen C.

Am J Cardiol. 2012 Dec 1;110(11):1561-7. doi: 10.1016/j.amjcard.2012.07.019. Epub 2012 Aug 31.

PMID:
22939581
45.

The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME.

Costessi A, Mahrour N, Sharma V, Stunnenberg R, Stoel MA, Tijchon E, Conaway JW, Conaway RC, Stunnenberg HG.

PLoS One. 2012;7(8):e42822. doi: 10.1371/journal.pone.0042822. Epub 2012 Aug 13.

46.

Automated TIMI frame counting using 3-d modeling.

ten Brinke GA, Slump CH, Stoel MG.

Comput Med Imaging Graph. 2012 Oct;36(7):580-8. doi: 10.1016/j.compmedimag.2012.07.001. Epub 2012 Aug 4.

PMID:
22867533
47.

Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry.

de Man FH, Tandjung K, Hartmann M, van Houwelingen KG, Stoel MG, Louwerenburg HW, Basalus MW, Sen H, Löwik MM, von Birgelen C.

EuroIntervention. 2012 Jul 20;8(3):336-44. doi: 10.4244/EIJV8I3A52.

48.

Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents.

Sen H, Tandjung K, Basalus MW, Löwik MM, van Houwelingen GK, Stoel MG, Louwerenburg HW, de Man FH, Linssen GC, Nijhuis R, Nienhuis MB, Verhorst PM, van der Palen J, von Birgelen C.

EuroIntervention. 2012 Oct;8(6):664-71. doi: 10.4244/EIJV8I6A104.

49.

DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population.

Tandjung K, Basalus MW, Sen H, Jessurun GA, Danse PW, Stoel M, Linssen GC, Derks A, van Loenhout TT, Nienhuis MB, Hautvast RW, von Birgelen C.

Am Heart J. 2012 Apr;163(4):557-62. doi: 10.1016/j.ahj.2012.02.001.

PMID:
22520520
50.

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.

von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH.

J Am Coll Cardiol. 2012 Apr 10;59(15):1350-61. doi: 10.1016/j.jacc.2012.01.008. Epub 2012 Feb 15.

Supplemental Content

Support Center